Roche to Introduce ATR Inhibitor RP-3500 for $1.2 Billion
On June 1, Repare Therapeutics announced that it has entered into a global license and collaboration agreement with Roche for the development and commercialization of camonsertib (RP-3500).
Under the agreement, Roche will undertake the development of camonsertib, with the potential to expand development into other oncology and multiple combination studies. Repare will receive an upfront payment of $125 million and is eligible to receive up to $1.2 billion in potential development, regulatory, commercial and sales milestones, as well as royalties on global net product sales.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lonza acquires Roche US biologics facility for $1.2 billion
-
Lonza acquires biologics plant from Roche for $1.2 billion
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Aβ monoclonal antibody is broken again, Alzheimer's disease new drug research and development is a long way, who can break the deadlock?
-
Roche's Next-generation C5 Complement Inhibitor Crovalimab Successfully Completed Phase III Study in China
-
Roche's TIGIT Monoclonal Antibody Collapses Again, And A Large Number of Domestic Biopharmaceutical Companies are Deployed
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
-
Roche's Potential 'First-in-class' Bispecific Therapy Wins EU CHMP Support
-
Novartis has the most new drugs approved, and Roche's new drugs have the highest value!
-
Roche's 2020 annual report is released, sales of innovative drugs surge
Recommend Reading
-
![LyondellBasell Expands Laboratory Capabilities at Suzhou Technology Center]()
LyondellBasell Expands Laboratory Capabilities at Suzhou Technology Center
-
![Profit Crushed, Layoffs and Restructuring Follow: What WACKER Chemie’s 2025 Performance Reveals]()
Profit Crushed, Layoffs and Restructuring Follow: What WACKER Chemie’s 2025 Performance Reveals
-
![Henkel to Acquire Olaplex in $1.4 Billion Deal]()
Henkel to Acquire Olaplex in $1.4 Billion Deal
-
![Europe’s Petrochemical Industry Slashes Cracker Capacity in Historic Retrenchment]()
Europe’s Petrochemical Industry Slashes Cracker Capacity in Historic Retrenchment
-
![Due to Supply Chain Disruptions, A Major MDI/TDI Facility in the Middle East has Suddenly Shut Down!]()
Due to Supply Chain Disruptions, A Major MDI/TDI Facility in the Middle East has Suddenly Shut Down!
-
![Recent Acetic Acid Market Trending Weakly in China]()
Recent Acetic Acid Market Trending Weakly in China
-
![From January to August 2025, China's cumulative production of bisphenol A reached 3,150,000 tons]()
From January to August 2025, China's cumulative production of bisphenol A reached 3,150,000 tons
-
![DMF Market Runs Stable with a Slight Tendency to Strengthen]()
DMF Market Runs Stable with a Slight Tendency to Strengthen
-
![Sulfur Dioxide Properties & Uses: Industrial, Preservative & Safety Guide]()
Sulfur Dioxide Properties & Uses: Industrial, Preservative & Safety Guide
-
![Caustic Soda Prices Continue to Decline in January]()
Caustic Soda Prices Continue to Decline in January
